Arthritis Clinical Trials

Primary objective

• To evaluate the mean change from baseline of activity impairment as measured by the Work Productivity and Activity Impairment - General Health Problem Questionnaire instrument in patients with rheumatic diseases (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis) treated with adalimumab, over a period of two years, as prescribed by the rheumatologist in a normal clinical setting and in accordance with the terms of the Greek Summary Product Characteristics

Secondary objectives

To assess the effect of adalimumab at 3, 6, 12, 18 and 24 months of treatment as:

• Evolution of all components of Work Productivity and Activity Impairment - General Health Problem Questionnaire (absenteeism, presenteeism, percentage of overall work and activity impairment due to the disease) in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis patients
• Change of Disease Activity Score for 28 joints and Health Assessment Questionaire Scoring in Rheumatoid Arthritis patients
• Alteration of Bath Ankylosing Spondylitis Disease Activity Index scoring in Ankylosing Spondylitis patients
• Alteration of Psoriatic Arthritis Response Criteria scoring in Psoriatic Arthritis patients
• Effect on sleep disturbances as measured by Medical Outcomes Study Sleep Scale instrument in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis patients
• Correlation of mean change of Disease Activity Score for 28 joints and Health Assessment Questionnaire, Bath Ankylosing Spondylitis Disease Activity Index and Psoriatic Arthritis Response Criteria from baseline until 24 months of treatment with number of missed workdays, degree of work performance and sleep disturbances in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis patients.